Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 0.504 EUR 3.7% Market Closed
Market Cap: 9.5m EUR

Biosynex SA
Investor Relations

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Larry Abensur
Chairman & CEO
No Bio Available
Mr. Thomas Lamy
Deputy CEO & Director
No Bio Available

Contacts

Address
GRAND EST
Illkirch-Graffenstaden
22 Boulevard Sebastien Brant
Contacts
+33388787887
www.biosynex.com